Floatz logo

Toripalimab

Pancreatic Neoplasms

Ruijin Hospitalmonoclonal_antibodyPhase 2Active
B
62/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
51/ 100
Competitive Position
81/ 100

Competitive context

25 Active assets in the Pancreatic Neoplasms cohort.

Asset / SponsorPhaseRating
Desflurane
Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran
Phase 4BB
NORMAL HUMAN SERUM ALBUMIN
Region Skane
Phase 4BB
Octreotide Pamoate
University of Liverpool
Phase 3B
bi 2536
Boehringer Ingelheim
Phase 2B
Qingyihuaji Optimized Formula
Fudan University
Phase 3B

View all 50 →

Same molecule, other indications

Toripalimab is also rated in:

renal cell carcinomaDormant
BB
Indicative ·
67 / 100
View asset →
extranodal nasal NK/T cell lymphomaDormant
BB
Indicative ·
66 / 100
View asset →
ToripalimabDormant
BB
Indicative ·
66 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →